Agilon health/$AGL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Agilon health
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
- Ticker
- $AGL
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 856
- Headquarters
- Westerville, United States
- Website
- www.agilonhealth.com
Agilon health Metrics
BasicAdvanced
$1.4B
-
-$13.97
3.05
-
Price and volume
Market cap
$1.4B
Beta
3.05
52-week high
$133.04
52-week low
$7.48
Average daily volume
210K
Financial strength
Current ratio
1.081
Quick ratio
0.976
Long term debt to equity
0.081
Total debt to equity
0.147
Interest coverage (TTM)
-36.44%
Profitability
EBITDA (TTM)
-239.715
Gross margin (TTM)
0.23%
Net profit margin (TTM)
-3.92%
Operating margin (TTM)
-4.29%
Effective tax rate (TTM)
-0.26%
Revenue per employee (TTM)
$6,920,000
Management effectiveness
Return on assets (TTM)
-9.61%
Return on equity (TTM)
-78.94%
Valuation
Price to revenue (TTM)
0.238
Price to book
6.26
Price to tangible book (TTM)
8.51
Price to free cash flow (TTM)
-13.312
Free cash flow yield (TTM)
-7.51%
Free cash flow per share (TTM)
-6.378
Growth
Revenue change (TTM)
0.32%
Earnings per share change (TTM)
-26.87%
3-year revenue growth (CAGR)
22.91%
3-year earnings per share growth (CAGR)
37.84%
What the Analysts think about Agilon health
Analyst ratings (Buy, Hold, Sell) for Agilon health stock.
Analyst projections of the future price of Agilon health stock.
Bulls say / Bears say
Agilon’s turnaround became clearer in the second quarter: it reported $18 million of net income versus a $104 million loss a year earlier, and raised its 2026 adjusted EBITDA guidance to $75–95 million from $10–40 million. That points to improving profitability, if the gains hold. (SEC)
Better reimbursement is lifting revenue per member: second-quarter capitation rates per member rose 19% year on year, helped by CMS funding and improved payer contract terms. This could cushion the effect of a smaller membership base. (SEC)
Recent expansions with Springfield Clinic and The Jackson Clinic extend Agilon’s reach into traditional Medicare ACOs, with the two partnerships expected to cover about 30,000 additional beneficiaries. This offers a route to grow beyond its Medicare Advantage base. (Agilon Health, Agilon Health)
Membership is still shrinking: Medicare Advantage members fell 12% year on year by June 2026, while ACO beneficiaries fell 3%. A smaller platform may constrain future growth even as pricing improves. (SEC)
Cash generation remains a concern: Agilon used $33.6 million of operating cash in the first half of 2026 despite reporting net income. Continued cash outflows could limit its room to invest in growth. (SEC)
Profitability is highly exposed to medical-cost estimates: management said a 1% change in cost trend could shift medical margin by about $50 million and adjusted EBITDA by about $25 million. The second-quarter margin also benefited from favourable current- and prior-period claims development, which may not recur. (Investing.com, SEC)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
Agilon health Financial Performance
Revenues and expenses
Agilon health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Agilon health News
AllArticlesVideos
Funds containing Agilon health
Fund name | Fund size | $AGL weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.